Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist administered once weekly, produces superior weight loss and glycemic control compared to semaglutide and dulaglutide in patients with type 2 diabetes and obesity.
For patients with T2DM or obesity, tirzepatide offers a potent once-weekly injection option that improves weight, blood sugar, and lipid profiles more effectively than some existing GLP-1 drugs. Due to potential gastrointestinal side effects, treatment should start at low doses and escalate slowly. Access may be limited by cost, requiring engagement with healthcare policymakers and insurers.
In a study to confirm the efficacy of tirzepatide compared to semaglutide, tirzepatide was found to be superior and noninferior to semaglutide with respect to weight reductions and dose-dependent reductions in glycated hemoglobin level... In phase 1 and phase 2 trials, tirzepatide demonstrated dose-dependent reduction in HbA1c (up to 2.4%) and body weight (up to 11.3 kg) in patients with T2 DM, suggesting its superiority to dulaglutide.
Why this rating
The paper cites Phase 1, 2, and 3 randomized controlled trials (RCTs) and head-to-head comparisons, which constitute high-quality evidence, though it is an editorial summary rather than primary data publication.
Source
Advent of tirzepatide: boon for diabetic and obese?
Amrit Bhusal · Annals of Medicine and Surgery · 2023
DOI 10.1097/ms9.0000000000000173
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →